Susceptibility of Feline Immunodeficiency Virus/Human Immunodeficiency Virus Type 1 Reverse Transcriptase Chimeras to Non-Nucleoside RT Inhibitors
- 1 January 2004
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 65 (1) , 244-251
- https://doi.org/10.1124/mol.65.1.244
Abstract
To map the determinants of the lack of susceptibility of feline immunodeficiency virus (FIV) reverse transcriptase (RT) to anti human immunodeficiency virus type 1 (HIV-1) non-nucleoside RT inhibitors (NNRTIs), a variety of chimeric HIV-1/FIV RTs were constructed. The majority of chimeric RTs had an affinity (Km) for their natural substrates comparable with that of the wild-type HIV-1 and FIV RTs, but their catalytic efficacy was decreased. Whereas HIV-1 RT could be made entirely insensitive to NNRTIs by exchanging the amino acid sequence 97 through 205 of FIV RT, none of the reverse FIV/HIV-1 RT chimeras gained susceptibility to NNRTIs. The amino acids that are thought to be involved in NNRTI susceptibility and that are different from those in HIV-1 RT have also been introduced in FIV RT. These mutant RTs gained virtually no susceptibility to efavirenz or capravirine. Vice versa, when these HIV-1-specific amino acids were replaced by their FIV RT counterparts in HIV-1 RT, susceptibility to the NNRTIs was lost. Thus, replacing segments or substituting relevant amino acids in FIV RT by their HIV-1 RT counterparts did not suffice to make FIV RT sensitive toward NNRTIs and was often accompanied by a decrease or even total loss of polymerase activity. It is postulated that, in contrast to the results found for HIV-1/HIV-2 RT chimeras and supported by the crystal structure of HIV-2 RT, there exist significant differences in the structure and/or flexibility of FIV RTs that may prevent NNRTIs from interacting with the FIV RT.Keywords
This publication has 27 references indexed in Scilit:
- Cloning, expression, purification, and crystallisation of HIV-2 reverse transcriptaseProtein Expression and Purification, 2002
- Chimeric Human Immunodeficiency Virus Type 1 and Feline Immunodeficiency Virus Reverse Transcriptases: Role of the Subunits in Resistance/Sensitivity to Non-Nucleoside Reverse Transcriptase InhibitorsMolecular Pharmacology, 2002
- DiscussionBiochemical Pharmacology, 1999
- Resistance to non-nucleoside inhibitors of HIV-1 reverse transcriptaseDrug Resistance Updates, 1999
- Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitorProceedings of the National Academy of Sciences, 1997
- Structure of unliganded HIV-1 reverse transcriptase at 2.7 å resolution: implications of conformational changes for polymerization and inhibition mechanismsStructure, 1996
- Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitorsNature Structural & Molecular Biology, 1995
- Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitorsAntimicrobial Agents and Chemotherapy, 1993
- Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitorsAntimicrobial Agents and Chemotherapy, 1992
- Structure of HIV-1 reverse transcriptase/DNA complex at 7 Å resolution showing active site locationsNature, 1992